In ER-positive tumors, AR has an anti-proliferative effect by antagonizing ER, by binding to a subset of estrogen response elements (EREs); it can prevent the activation of target genes which mediate the stimulatory effects of 17-beta-estradiol on breast cancer cells [51,52]. Here, ESR1 is linked to breast carcinoma.